Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors
- PMID: 21632716
- DOI: 10.4049/jimmunol.1002067
Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors
Abstract
STAT3 signaling constitutes an important negative feedback mechanism for the maintenance of immune homeostasis, a suppressive signal for the Th1 immune response in murine macrophages, and a cancer immune evasion signal in various immune cells. The strategy for STAT3 signal inhibition should be considered, because these features could impede effective cancer immunotherapy. We have evaluated the effects of STAT3 inactivation in dendritic cells (DCs) on immune responses in mice and humans. DCs derived from LysMcre/STAT3(flox/flox) mice displayed higher cytokine production in response to TLR stimulation, activated T cells more efficiently, and were more resistant to the suppression of cytokine production by cancer-derived immunosuppressive factors compared with DCs from control littermates. Antitumor activities of STAT3-depleted and control DCs were compared by intratumoral administration of gp70 Ag peptide-pulsed DCs in the therapeutic MC38 tumor model. Intratumoral administration of STAT3-depleted DCs significantly inhibited MC38 tumor growth of both injected and nontreated remote tumors. The inhibition was accompanied by an increase in gp70-specific T cell response as well as in systemic Th1 immune response. STAT3-depleted human DCs with adenoviral STAT3 short hairpin RNA were also capable of producing more cytokines with TLR stimulation and more resistant to cancer-derived factors, and they induced tumor Ag-specific T cells more efficiently than control DCs. The identified role of DC STAT3 signaling in both in vivo therapeutic tumor models in mice and in vitro-specific T cell induction in humans indicates that STAT3-inactivated DCs may be a promising approach for cancer immunotherapy.
Similar articles
-
Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.Cancer Res. 2005 Nov 1;65(21):10059-67. doi: 10.1158/0008-5472.CAN-05-1692. Cancer Res. 2005. PMID: 16267032
-
Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.Oncol Rep. 2006 Dec;16(6):1317-24. Oncol Rep. 2006. PMID: 17089056
-
Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.Cancer Res. 2003 Jun 1;63(11):2844-54. Cancer Res. 2003. PMID: 12782590
-
RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.Expert Rev Anticancer Ther. 2009 Jan;9(1):97-114. doi: 10.1586/14737140.9.1.97. Expert Rev Anticancer Ther. 2009. Retraction in: Expert Rev Anticancer Ther. 2011 Nov;11(11):1778. doi: 10.1586/era.11.137 PMID: 19105710 Retracted. Review.
-
Species-specific properties and translational aspects of canine dendritic cells.Vet Immunol Immunopathol. 2013 Feb 15;151(3-4):181-92. doi: 10.1016/j.vetimm.2012.12.003. Epub 2012 Dec 13. Vet Immunol Immunopathol. 2013. PMID: 23280245 Review.
Cited by
-
STAT3, a Master Regulator of Anti-Tumor Immune Response.Cancers (Basel). 2019 Aug 30;11(9):1280. doi: 10.3390/cancers11091280. Cancers (Basel). 2019. PMID: 31480382 Free PMC article. Review.
-
Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive.Br J Cancer. 2014 Aug 26;111(5):927-32. doi: 10.1038/bjc.2014.367. Epub 2014 Jul 24. Br J Cancer. 2014. PMID: 25058349 Free PMC article.
-
MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells.Nucleic Acid Ther. 2018 Aug;28(4):225-232. doi: 10.1089/nat.2017.0695. Epub 2018 Jun 12. Nucleic Acid Ther. 2018. PMID: 29893623 Free PMC article.
-
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Front Immunol. 2013 Dec 2;4:419. doi: 10.3389/fimmu.2013.00419. Front Immunol. 2013. PMID: 24348482 Free PMC article. Review.
-
Targeting STAT3 in Cancer Immunotherapy.Mol Cancer. 2020 Sep 24;19(1):145. doi: 10.1186/s12943-020-01258-7. Mol Cancer. 2020. PMID: 32972405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous